Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | ATM | Q13315 | 2/20 | 0.46 |
| ▸ | SLC6A1 | P30531 | 2/20 | 0.44 |
| ▸ | SLC6A11 | P48066 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | SLC6A13 | Q9NSD5 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | PBK | Q96KB5 | 3/20 | 0.42 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.41 |
| ▸ | CHEK1 | O14757 | 3/20 | 0.40 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.40 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.40 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1321300 | 1.00 | MAPK1 (0.50) | MAPK1OPRK1KDM4EALDH1A1ATM | |
| SCHEMBL11949315 | 1.00 | MAPK1 (0.50) | MAPK1OPRK1KDM4EALDH1A1ATM | |
| Hydrochloric Acid SCHEMBL30636640 | 0.98 | MAPK1 (0.49) | MAPK1OPRK1KDM4EALDH1A1ATM | |
| Acetic Acid SCHEMBL9994796 | 0.96 | MAPK1 (0.48) | MAPK1OPRK1KDM4EALDH1A1ATM | |
| SCHEMBL25040356 | 0.94 | KDM4E (0.46) | MAPK1OPRK1KDM4EALDH1A1ATM | |
| SCHEMBL21431245 | 0.92 | EPHX1 (0.47) | MAPK1OPRK1KDM4EALDH1A1ATM | |
| Trifluoroacetic Acid SCHEMBL23779162 | 0.88 | MAPK1 (0.43) | MAPK1OPRK1KDM4EALDH1A1ATM | |
| Trifluoroacetic Acid SCHEMBL23779199 | 0.88 | MAPK1 (0.43) | MAPK1OPRK1KDM4EALDH1A1ATM | |
| SCHEMBL39918 | 0.88 | — | — | |
| SCHEMBL39850 | 0.88 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 189 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12030878-B2 | Substituted indole ether compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-07-09 | — | — | US | claimed |
| US-20130172562-A1 | PROCESS FOR THE PREPARATION OF A SINGLE ENANTIOMER OF 3-AMINOPIPERIDINE DIHYDROCHLORIDE | DR. REDDY'S LABORATORIES, INC. (US) | 2013-07-04 | — | — | US | claimed |
| EP-2582671-A2 | PROCESS FOR THE PREPARATION OF A SINGLE ENANTIOMER OF 3-AMINOPIPERIDINE DIHYDROCHLORIDE | Dr. Reddy's Laboratories Ltd. (IN) | 2013-04-24 | — | — | EP | claimed |
| WO-2011160037-A2 | PROCESS FOR THE PREPARATION OF A SINGLE ENANTIOMER OF 3-AMINOPIPERIDINE DIHYDROCHLORIDE | DR. REDDY'S LABORATORIES LTD. (IN) | 2011-12-22 | — | — | WO | claimed |
| JP-5112554-A | — | — | None | — | — | JP | disclosed |
| CN-122036690-A | Heteroaromatic ring compound, pharmaceutical composition and application thereof | 马应龙药业集团股份有限公司 | 2026-05-15 | — | — | CN | disclosed |
| US-20250326732-A1 | CHROMEN-2-ONE MODULATORS OF POLRMT | PRETZEL THERAPEUTICS, INC. (US) | 2025-10-23 | — | — | US | disclosed |
| US-20250017940-A1 | SELECTIVE PEPTIDOMIMETIC MODULATORS OF CAV2.2 (N-TYPE) VOLTAGE-GATED CALCIUM CHANNELS AND USES THEREOF | NEW YORK UNIVERSITY (US) | 2025-01-16 | — | — | US | disclosed |
| WO-2024253416-A1 | PYRIMIDINE/PYRIDINE DERIVATIVES OR SALTS THEREOF AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | YUHAN CORPORATION (KR) | 2024-12-12 | — | — | WO | disclosed |
| US-12116343-B2 | Inhibitors of APOL1 and methods of using same | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2024-10-15 | — | — | US | disclosed |
| EP-4434980-A1 | MULTIFUNCTIONAL COMPOUND CAPABLE OF DEGRADING BTK KINASE, AND COMPOSITION AND USE | Hangzhou HealZen Therapeutics Co., Ltd. (CN) | 2024-09-25 | — | — | EP | disclosed |
| CN-116143757-B | Multifunctional compound, composition and application of degradable BTK kinase | 杭州和正医药有限公司 | 2024-07-05 | — | — | CN | disclosed |
| US-20060100236-A1 | For therapy of disorder of reduced motility of gastrointestinal tract, chronic constipation, functional dyspepsia, delayed gastric emptying, gastroesophageal reflux disease, gastroparesis, diabetic and iodiopathic gastropathy, post-operative ileus, intestinal pseudo-obstruction, irritable bowel syndrome | THERAVANCE, INC. (US) | 2006-05-11 | — | — | US | disclosed |
| US-20060100426-A1 | Quinolinone-carboxamide compounds | THERAVANCE, INC. | 2006-05-11 | — | — | US | disclosed |
| US-20050197335-A1 | 1-isopropyl-1H-indazole-3-carboxylic acid {(1S,3R,5R)-8-[2-(4-acetylpiperazin-1-yl)-ethyl]8-azabicyclo[3.2.1]oct-3-yl}amide; improved pharmacokinetic, bioavailability; gastrointestinal disorders: irritable bowel syndrome (IBS), chronic constipation, dyspepsia; CNS behavioral, mood disorder | THERAVANCE BIOPHARMA R&D IP, LLC | 2005-09-08 | — | — | US | disclosed |
| WO-2005080389-A1 | INDAZOLE-CARBOXAMIDE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS | THERAVANCE, INC. (US) | 2005-09-01 | — | — | WO | disclosed |
| EP-0342675-B1 | Novel quinolonecarboxylic acid derivatives | CHUGAI PHARMACEUTICAL CO LTD (JP) | 1995-01-25 | — | — | EP | disclosed |
| JP-H05112554-A | NEW QUINOLONECARBOXYLIC ACID DERIVATIVE | CHUGAI PHARMACEUT CO LTD | 1993-05-07 | — | — | JP | disclosed |
| US-5051509-A | Antibiotics | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 1991-09-24 | — | — | US | disclosed |
| EP-0342675-A2 | Novel quinolonecarboxylic acid derivatives | Chugai Seiyaku Kabushiki Kaisha (JP) | 1989-11-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250326732-A1 | CHROMEN-2-ONE MODULATORS OF POLRMT | POLRMT, TFAM, POLM | MAPK1 2069/4885OPRK1 3192/4885KDM4E 2158/4885 |
| US-12116343-B2 | Inhibitors of APOL1 and methods of using same | APOL1, APOB, NPC1L1 | MAPK1 2302/4885OPRK1 2088/4885KDM4E 4664/4885 |
| US-20130172562-A1 | PROCESS FOR THE PREPARATION OF A SINGLE ENANTIOMER OF 3-AMINOPIPERIDINE DIHYDROCHLORIDE | RAC3, RAC2, RAPGEF4 | MAPK1 714/4885OPRK1 1220/4885KDM4E 1184/4885 |
| US-20050197335-A1 | 1-isopropyl-1H-indazole-3-carboxylic acid {(1S,3R,5R)-8-[2-(4-acetylpiperazin-1-yl)-ethyl]8-azabicyclo[3.2.1]oct-3-yl}amide; improved pharmacokinetic, bioavailability; gastrointestinal disorders: irritable bowel syndrome (IBS), chronic constipation, dyspepsia; CNS behavioral, mood disorder | HTR4, HTR5A, HTR3C | MAPK1 1687/4885OPRK1 113/4885KDM4E 1798/4885 |
| US-20060100236-A1 | For therapy of disorder of reduced motility of gastrointestinal tract, chronic constipation, functional dyspepsia, delayed gastric emptying, gastroesophageal reflux disease, gastroparesis, diabetic and iodiopathic gastropathy, post-operative ileus, intestinal pseudo-obstruction, irritable bowel syndrome | GIPR, GPR4, GPR119 | MAPK1 1743/4885OPRK1 83/4885KDM4E 3939/4885 |
| US-20060100426-A1 | Quinolinone-carboxamide compounds | HTR4, HTR5A, HTR2C | MAPK1 3303/4885OPRK1 61/4885KDM4E 1306/4885 |
| US-12030878-B2 | Substituted indole ether compounds | TLR7, TLR8, TLR1 | MAPK1 442/4885OPRK1 109/4885KDM4E 2242/4885 |
| US-20250017940-A1 | SELECTIVE PEPTIDOMIMETIC MODULATORS OF CAV2.2 (N-TYPE) VOLTAGE-GATED CALCIUM CHANNELS AND USES THEREOF | CACNA1B, CACNA1E, CACNA1D | MAPK1 3305/4885OPRK1 166/4885KDM4E 3241/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.